722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster II

Trial in progress A phase 3 randomized double blind placebo controlled study of axatilimab and corticosteroids as initial treatment for moderate to severe chronic graft versus host disease

An optimized MSC product promotes GvHD prophylaxis through exosome mediated regulatory T cell induction

Peripheral plasmablast expansion as a predictor and therapeutic target in chronic GVHD

Fludarabine and total body irradiation 800 cgy or 1125 cgy for allogeneic stem cell transplant using graft versus host disease prophylaxis with post transplant cyclophosphamide and tacrolimus without mycophenolate mofetil OmitMMF trial

GVHD intel 1 0 A scalable HLA enhanced machine learning model for predicting acute and chronic GVHD

Graft vs host disease outcomes in early tacrolimus withdrawal following allogeneic hematopoietic stem cell transplant

Multicenter real world experience of belumosudil treatment in heavily pretreated patients with steroid refractory chronic graft versus host disease Clinical outcomes and risk factor analysis for failure free survival

Peri transplant ruxolitinib therapy significantly improves GVHD free relapse free survival rates in transplantation for myelofibrosis

Mesenchymal stem cells for treating gastrointestinal involved steroid refractory acute graft versus host disease A multicenter single arm pivotal clinical Trial

The role of microbial metabolites in fecal microbiota transplantation in patients with acute gvhd of the gut

Identification of CD4 T cells targeting DM sensitive antigens presented on mismatched HLA DP alleles as mediators of a selective graft versus leukemia effect

Real world experience of alpha 1 antitrypsin in steroid refractory acute graft versus host disease Higher durable response rate compared to ruxolitinib

Phase II Study of post transplant cyclophosphamide based graft versus host disease prophylaxis after HLA mismatched unrelated donor transplantation and reduced intensity conditioning Results from the NMDP sponsored access expansion Study

Donor and recipient age related differences in immunological reconstitution affect development of chronic graft versus host disease

Vedolizumab for treating steroid refractory lower gastrointestinal acute graft versus host disease  a single center real world study

Gut microbiota recovery via butyrate supplementation prevents acute graft versus host disease after allogeneic hematopoietic stem cell transplantation

Low incidence of agvhd with ptcy tacrolimus and post engraftment low dose ATG based GvHD prophylaxis in haplo identical donor transplantation and establish of new predict score for grade II iv agvhd

Development and evaluation of a protein language model based prediction model for acute graft versus host disease in HLA mismatched hematopoietic stem cell transplantation